{"id":"F2007B01049","name":"National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 6 of 2000)","slug":"national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-6-of-2000","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":62528,"registerId":"commonwealth-F2007B01049-current","compilationNumber":null,"startDate":"2026-04-02","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 6 of 2000)","content":"COMMONWEALTH OF AUSTRALIA\n\nNational Health Act 1953\n\nPHARMACEUTICAL BENEFITS\n\nDECLARATION UNDER SUBSECTION 85 (2AA)\n\nNo. PB 6 of 2000\n\nI, BRETT ANTHONY LENNON, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Aged Care and Delegate of the Minister for Health and Aged Care, having in accordance with subsection 85 (2AB) of the National Health Act 1953 obtained the advice of the Pharmaceutical Benefits Advisory Committee, pursuant to subsection 85 (2AA) of the National Health Act 1953, hereby make the following Declaration:\n\n1.  This Declaration shall come into operation on 1 May 2000.\n\n2. The drugs and medicinal preparations specified in the Schedule to this Declaration shall cease to be drugs and medicinal preparations to which Part VII of the National Health Act 1953 applies.\n\nTHE SCHEDULE\n\nErythromycin Estolate\n\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nDated this 4th day of April 2000.\n\nBRETT ANTHONY LENNON\n\nAssistant Secretary\n\nPharmaceutical Benefits Branch\n\nDepartment of Health and Aged Care\n\nDelegate of the Minister for Health and Aged Care","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-batch","completionTokens":2220},"content_quality":"ok","complexity_score":1,"scope_assessment":{"changed":false,"description":"The declaration maintains its original narrow administrative scope of removing a single specified drug from the Pharmaceutical Benefits Scheme. It has not expanded to include additional drugs or broader policy changes."},"complexity_factors":["Only one drug listed in the schedule","No conditional provisions, exceptions, or triggers","No definitions section or interpretation clauses","Straightforward revocation of existing PBS status"],"plain_english_summary":"The government has removed Erythromycin Estolate from PBS subsidy, so patients will no longer pay concession or standard co-pay rates and must buy it at full private price. Prescribers may still write prescriptions but they will be processed as private scripts. The Department of Health, following PBAC advice, has declared the relevant PBS authority in the National Health Act no longer applies to this drug, ending its taxpayer subsidy."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-6-of-2000","history":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-6-of-2000/history","analysis":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-6-of-2000/analysis","conflicts":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-6-of-2000/conflicts","importantCases":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-6-of-2000/important-cases","documents":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-6-of-2000/documents"}}